Dynamic Process of Prostate Cancer Metastasis to Bone

Kwanchanit Tantivejkul, Linda M. Kalikin, and Kenneth J. Pienta*

Departments of Urology and Internal Medicine, Division of Hematology and Oncology, The Michigan Urology Center at The University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109

Abstract Prostate cancer metastasis to the bone occurs at high frequency in patients with advanced disease, causing significant morbidity and mortality. Over a century ago, the “seed and soil” theory was proposed to explain organ-specific patterns of metastases. Today, this theory continues to be relevant as we continue to discover factors involved in the attraction and subsequent growth of prostate cancer cells to the bone. These include the accumulation of genetic changes within cancer cells, the preferential binding of cancer cells to bone marrow endothelial cells, and the release of cancer cell chemoattractants from bone elements. A key mediator throughout this metastatic process is the integrin family of proteins. Alterations in integrin expression and function promote dissociation of cancer cells from the primary tumor mass and migration into the blood stream. Once in circulation, integrins facilitate cancer cell survival through interactions between other cancer cells, platelets, and endothelial cells of the target bone. Furthermore, dynamic changes in integrins and in integrin-associated signal transduction aid in the extravasation of cancer cells into the bone and in expansion to a clinically relevant metastasis. Thus, we will review the critical roles of integrins in the process of prostate cancer bone metastasis, from the escape of cancer cells from the primary tumor, to their survival in the harsh “third microenvironment” of the circulation, and ultimately to their attachment and growth at distant bone sites. J. Cell. Biochem. 91: 706–717, 2004. © 2003 Wiley-Liss, Inc.

Key words: prostate cancer; integrins; metastasis; cell adhesion; bone; signal transduction; RhoGTPases

Prostate cancer is the second most common cause of cancer-related deaths among men in the United States [Jemal et al., 2003]. It is estimated that 220,900 new cases will be diagnosed and 28,900 deaths will occur in 2003. Approximately 90% of advanced stage prostate cancer patients develop bone lesions causing morbidity that includes bone pain, immobility, hematopoietic compromises, and spinal cord compression [Bubendorf et al., 2000; Rubin et al., 2000]. Current treatments are not curative, and patients have a median survival time of 9–12 months after becoming hormone refractory [Cheville et al., 2002].

Ellis et al. [2003] reported that prostate-specific antigen- (PSA-) expressing epithelial cells were detected in bone marrow samples from 60 of 126 (54%) patients with localized prostate cancer before radical prostatectomy, while only 33 of 138 (24%) patients had detectable PSA-expressing epithelial cells in peripheral blood. This finding supports the preferential enrichment of cancer cells in the bone marrow as an early metastatic event and leads to many interesting questions pertinent to prostate cancer metastasis. How do the cancer cells outgrow and escape from the primary site? How do they survive shear forces present in the circulation and evade immunosurveillance? How do these cells interact with the target bone endothelium? What factors in the bone microenvironment attract prostate cancer cells and prompt them to initiate growth? Understanding the biological processes leading to the establishment of clinically relevant bone metastases is not just an intellectual exercise as the answers to these questions may lead to invaluable therapeutic strategies to treat the currently incurable disease of advanced prostate cancer.

HISTORICAL PERSPECTIVE OF CANCER METASTASIS

Metastasis is a multi-step process that includes growth in a primary organ, neoangi-
genesis, intravasation into and survival in circulation, attachment to a distant target organ, extravasation at that site, and growth of a secondary neoplasm and, as such, appears to be an inefficient process (Fig. 1). While organ-specific localization of luciferase-labeled PC-3 human prostate cancer cell line cells was visualized by non-invasive imaging 15 min post-intracardiac injection in immunocompromised mice, no viable cells were detected 24 h later. Despite this indication that most of the injected cells were either dead or metabolically inactive, skeletal and soft tissue micrometastases were apparent on imaging several days later and were confirmed histologically and radiographically weeks later [Rosol et al., 2003]. Similarly, intravital videomicroscopy of various types of cancer showed that only 2% of cancer cells formed micrometastases [Luzzi et al., 1998; Varghese et al., 2002]. Furthermore, 99% of these micrometastases failed to form larger tumors, although numerous solitary cells remained detectable in the tissue months after injection [Naumov et al., 2001, 2002; MacDonald et al., 2002].

Stephen Paget [1889] was the first to present an explanation for the non-random patterns of cancer metastases. His “seed and soil” theory proposed that there was something about metastatic sites that promoted cancer cell growth similar to the tendency of seeds to grow in fertile soil, i.e., that factors in the environment at a metastatic site contributed to the proliferation of cancer cells there. Forty years later, James Ewing [1928] presented a different view

---

Fig. 1. Steps in prostate cancer metastasis to bone. Successful metastasis is a multi-step process that includes (1) growth and escape from a primary organ, (2) intravasation, (3) survival in circulation, (4) chemoattraction and extravasation, (5) and growth in bone through (6) cross-talks with osteoblasts and osteoclasts. These steps require the ability of cancer cells to adhere to and migrate across the surrounding extracellular matrix (ECM), actions mediated by the integrins.
proposing that cancer cells grew at a particular site because they were directed to that site by the direction of blood flow and lymphatics. It is likely that both of these theories are correct, at least in part. Ewing’s theory accounts for cancer growth in the draining lymph nodes and the liver, but Paget’s theory describes distal metastases that are organ-specific, such as metastases to the bone.

Isaiah Fidler [2002] redefined the modern “seed and soil” hypothesis as three principles. First, cancerous tissues contained heterogeneous subpopulations of cells with different angiogenic, invasive, and metastatic properties. Second, the metastatic process was selective for cells that survived the long journey to a distal organ. Finally, the success of the metastatic cells depended on the ability of those cells to interact and to utilize the “soil” provided in their new microenvironment. These properties are demonstrated by co-culture of an isolated mouse femur with PC-3 human prostate cancer cells (Fig. 2). As shown by scanning electron micrograph, after 3 days cells exhibiting diverse phenotypes are attached to the bone. We hypothesize that these variable morphologies may represent the heterogeneous population of prostate cancer cells that differentially responds to growth on bone. Alternatively, these pleomorphic cells may be in different stages of metastasis, as some appear anchored to the bone at the extended edges, perhaps “feeling” out the environment for chemotactic factors, while others seem to have formed firm adhesions with the bone, suggesting that they may have begun an invasive process.

**METASTATIC PROCESS AND INTEGRINS**

In normal prostate development, the interaction of prostate epithelial cells with surrounding stroma influences their growth, survival, and differentiation potential. Components of the surrounding stroma include numerous cell types, such as fibroblast, endothelial, neuroendocrine, and inflammatory cells; soluble growth factors; and insoluble laminin-rich extracellular matrix (ECM). Many of the steps in cancer metastasis involve changes in cell adhesion to adjacent cells and to the ECM. The cell surface receptor integrins have been implicated in these events since they mediate homotypic and heterotypic interactions of prostate cancer cells within their microenvironment. Integrins are composed of non-covalently associated \( \alpha \) and \( \beta \) subunits that play a role in mediating cell–cell interaction and cell–matrix interaction (Fig. 3). To date, genes for 16 \( \alpha \) and 8 \( \beta \) subunits have been identified. Both types of subunits encode single-pass transmembrane proteins with short cytoplasmic tails, except for the \( \beta 4 \) subunit which contains more than 100 residues [Longhurst and Jennings, 1998; Mizejewski, 1998].

![Fig. 2. Adhesion and invasion of PC-3 cells into mouse bone in an explant model. Several different cell morphologies are evident when PC-3 cells were co-cultured on mouse bone explant for 3 days, fixed with 2.5% glutaraldehyde in Sorenson’s buffer and prepared for scanning electron microscopy. These cells possibly represent either a heterogeneous population of prostate cancer cells or cells in different stages of bone metastasis. Some cells are elongated on the bone, perhaps in search of chemotactic factors (arrows). Other cells exhibit halo-like area around themselves, suggesting that they have initiated the invasion process (arrowheads).](image)
1999]. The α subunits contain Ca$^{2+}$-binding sites on the extracellular domain linked by a disulfide bond to the transmembrane portion [Argraves et al., 1987]. The β subunits contain four repeating units of cysteine-rich motifs proximal to the transmembrane region which are joined together by disulfide bonds [Argraves et al., 1987]. At least 22 different α/β heterodimers are known, and it is the particular combination of α and β subunits that determines ligand binding specificity. For example, fibronectin uniquely binds to the integrin heterodimer of α5 and β1 [Argraves et al., 1987].

**ESCAPE FROM THE PRIMARY TUMOR SITE**

Changes in integrin expression have been documented in primary prostate tumors and prostate cancer cell lines compared to normal prostate tissue (see Table I). Immunohistochemical studies of normal, prostatic intraepithelial neoplasia (PIN), and cancerous prostate tissues indicate that loss of the laminin receptor α6β4 integrins occurs with increasing malignancy [Davis et al., 2001]. Low Gleason sum score correlates with increased expression of the α3 and α6 integrin subunits, while high Gleason sum score correlates with low expression of α3 and negative expression of α6 integrin subunits compared to normal prostate tissue [Schmelz et al., 2002]. Furthermore, β1c integrin, an alternatively spliced variant of the β1 subunit abundantly expressed in normal prostate gland, inhibits cell proliferation [Fornaro et al., 1998] and is down-regulated in prostate carcinoma [Fornaro et al., 1996]. These changes in integrin expression are modulated upstream by many different factors including hormones and growth factors. For example, androgen-independent PC-3 prostate cancer cells transfected with androgen receptor (AR) express lower cell surface α6β4 integrins than the parental cells [Bonaccorsi et al., 2000]. Furthermore, these AR-positive cells exhibit decreased invasion through Matrigel, a laminin-rich reconstituted basement membrane, and less adhesion to laminin, thereby correlating reduced expression of α6β4 integrins with decreased invasiveness. Similarly, over expression of parathyroid hormone-related protein in PC-3 cells increases cell surface integrin expression and leads to an increase in cell adhesion to ECM proteins [Shen and Falzon, 2003].

The influence of integrin cell surface expression and interaction with the ECM in early prostate cancer progression is also illustrated by prostate acinar morphogenesis using a series of human prostatic epithelial cell lines. Nontumorigenic RWPE-1 prostate epithelial cell line form acini when grown in three-dimensional Matrigel cell cultures, while invasive WPE1-NB26 cells fail to form acini. In addition, RWPE-1 cells form acini on laminin-1, but not collagen or fibronectin, and are unable to form these structures when exposed to blocking antibodies for laminin-1 and laminin integrin receptor α6 or β1 subunits [Bello-DeOcampo et al., 2001a]. WPE1-NB26 cells show a lack of α6 integrin expression as well as abnormal β1 integrin expression [Bello-DeOcampo et al., 2001b]. Thus, alterations in the expression of laminin integrin receptors correlate with the ability of prostate cancer cells to escape the laminin-rich ECM support at a primary tumor site. This is further illustrated by the ability to accelerate rates of tumor growth in immuno-compromised mice injected with prostate cancer cells suspended in Matrigel, which is abrogated.

### Table I. Involvement of Integrins in Prostate Cancer Metastasis

<table>
<thead>
<tr>
<th>Integrins</th>
<th>Ligand*</th>
<th>Role in prostate cancer metastasis</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary tumor</td>
<td>α6β4</td>
<td>Laminin</td>
<td>Acinar morphogenesis</td>
</tr>
<tr>
<td>Circulatory system</td>
<td>α6β1</td>
<td>Laminin</td>
<td>Migration, invasion</td>
</tr>
<tr>
<td></td>
<td>αIIbβIIa</td>
<td>Fibrinogen, platelets</td>
<td>Microembolism, arrest in circulation</td>
</tr>
<tr>
<td></td>
<td>αvβ3</td>
<td>Vitronectin, endothelial cells</td>
<td>Arrest in circulation</td>
</tr>
<tr>
<td>Bone</td>
<td>α2β1</td>
<td>Collagen</td>
<td>Growth stimulation</td>
</tr>
<tr>
<td></td>
<td>α3β1</td>
<td>Collagen</td>
<td>Migration, invasion</td>
</tr>
<tr>
<td></td>
<td>αvβ3</td>
<td>Osteopontin, osteonectin</td>
<td>Growth stimulation, migration, invasion</td>
</tr>
</tbody>
</table>

*The major contributory role of integrin-mediated cell adhesion in prostate cancer metastasis is summarized. Although each integrin receptor can bind to multiple ligands and some ligand has multiple integrin receptors, only the contents of the ECM that are important in prostate cancer progression are listed.
by the inclusion of laminin cell adhesion peptide YIGSR [Passaniti et al., 1992]. Secretion of proteolytic enzymes by prostate cancer cells permits the cells to digest through the basement membrane to reach the microvasculature. Laminin-5 is a crucial protein in mediating cell stability, migration, and anchoring filament formation. Invasive prostate carcinoma shows a lack of protein expression of β3 and γ2 chains of laminin-5 and altered expression of the α3 chain [Hao et al., 2001]. Cleavage of laminin-5 by membrane-type 1 matrix metalloproteinase enhances migration of DU145 prostate carcinoma cells by two-fold compared to migration on uncleaved Laminin-5 thus promoting the escape of prostate cancer cells from the primary site [Udayakumar et al., 2003].

SURVIVAL IN THE CIRCULATORY SYSTEM

After prostate cancer cells cross the surrounding stroma, they enter the microvasculature in a process called intravasation and must evade assault by the immune system and the simple shear forces of blood flow. Cells appear to travel through the blood as part of a fibrin clot surrounded by other cancer cells and platelets to survive [Walz and Fenton, 1994], with platelets binding to cancer cells via the integrins αIIbβ3. Treatment with either anti-platelet antibodies or heparin inhibits platelet-tumor cell interaction [Borsig et al., 2001] and reduces lung metastasis [Stoelcker et al., 1996]. Similarly, blocking antibodies to αIIbβ3 inhibits lung colonization of mouse tail vein-injected DU145 cells [Trikha et al., 1998].

In the vasculature, thrombin may mediate cancer cell–platelet adhesion [Cooper et al., 2003] and may activate resting platelet integrins αIIbβ3 to induce platelet aggregation [Trikha and Nakada, 2002]. As well, activation of protease-activated receptor 1 (PAR1) on cancer cells by thrombin increases cell adhesion to platelets [Walz and Fenton, 1994]. Furthermore, we have previously shown that VCaP and PC-3 prostate cancer cell lines, both derived from osseous metastases, have increased PAR1 expression compared to normal prostate tissue [Chay et al., 2002]. Thus the ability of cancer cells to adhere and aggregate with platelets through the expression of cell surface receptors may protect them from shear stresses of the circulation and facilitate arrest in the microvasculature.

INTERACTION WITH THE ENDOTHELIUM

Hemodynamics may bring cancer cells into the bone marrow, but it alone does not explain the high frequency of prostate cancer metastasis to the bone [Yoneda, 1998]. Perhaps the presence of chemotactic gradients in the bone sinusoids contributes to the attraction, but the role cell–cell interaction plays cannot be ignored. We have shown that prostate cancer cells preferentially bind to bone marrow endothelial cells three- to five-fold more than to aortic, umbilical vein, or dermal vascular endothelial cells [Lehr and Pienta, 1998; Cooper et al., 2000b]. Furthermore, prostate cancer cells adhere preferentially directly to these bone endothelial cells and not to ECM proteins present in the bone in vitro, although the growth of bone marrow endothelial cells on bone ECM components significantly increases their affinity for PC-3 cells [Cooper et al., 2000b].

Adhesion and extravasation of prostate cancer cells from fenestrated bone marrow endothelium most likely occurs as a complex set of interactions between bone marrow endothelial cells, bone ECM components, and bone marrow stromal cells. The “dock and lock” mechanism was proposed as one explanation for extravasation and is similar to the inflammatory response of leukocytes [Honn and Tang, 1992] as both processes involve the arrest of circulating cells on the endothelium by low-affinity binding, induction of a firmer cell adhesion, extravasation, and invasion of the surrounding matrix [Buck, 1995]. During the “docking” step of inflammatory response, induced expression of P-selectin, a type of cell adhesion molecule on platelets, leukocytes, and endothelial cells, on activated endothelial cells is responsible for the low affinity binding of leukocytes to endothelial cells [Meyer and Hart, 1998]. Similarly, interaction of P-selectin with its ligand sialyl Lewisª carbohydrates is believed to cause the arrest of cancer cells in complex with platelets and leukocytes [Chopra et al., 1990; Bhatti et al., 1996; Borsig et al., 2001]. Indeed, elevated expression of sialyl Lewisª is detected at the surface of cancer cells and correlates with poor prognosis in prostate cancer [Martensson et al., 1995], and antibodies against sialyl Lewisª block adhesion of neutrophils and tumor cells to endothelial cells and platelets [Geng et al., 1990]. Furthermore, fewer lung metastasis and slower tumor growth occur when colon cancer
cells are implanted into P-selectin-deficient mice [Kim et al., 1998]. In breast and prostate cancer cells, adhesion to the microvascular endothelium of metastasis-prone tissues is also mediated in part by interactions between cancer-associated Thomsen–Friedenreich (TF) glycoantigen (Galβ1-3GalNAc) presenting on neoplastic cells and β-galactoside binding lectin galectin-3 expressing on endothelium [Lehr and Pienta, 1998; Ellerhorst et al., 1999; Glinsky et al., 2000, 2001; Nangia-Makker et al., 2002; Khaldoyanidi et al., 2003]. This adhesion is abrogated by blocking antibodies to β-galactoside-binding lectin, galectin-3, or TF antigen [Lehr and Pienta, 1998; Glinsky et al., 2003].

Similar to inflammatory response of leukocytes, the “locking” of prostate cancer cells to endothelial cells is facilitated through the complex collaboration of integrins. We have previously reported that β1 integrin was not involved in PC-3 prostate cancer cell–endothelial cell adhesion [Cooper et al., 2000a]. However, a more recent study showed that blocking antibodies to this subunit inhibited adhesion of PC-3 cells to bone marrow endothelial cells by 64% [Scott et al., 2001]. These conflicting results suggest the involvement of other integrins or cell adhesion molecules in prostate cancer cell adhesion to the endothelium. Indeed, cooperativity between αvβ3, zβ1 and zβ1 integrins is necessary for PC-3 and DU145 cell adhesion to interleukin-1-stimulated human umbilical vein endothelial cells [Romanov and Goligorsky, 1999].

**BONE MICROENVIRONMENT**

Once cancer cells have reached the bone, they must utilize the bone microenvironment to survive and propagate. In a review of bone scans from 27 patients with limited skeletal involvement, the distribution pattern of early prostate cancer metastases was similar to the distribution of normal adult bone marrow [Imbriaco et al., 1998]. This observation supports Ewing’s theory that cancer cell delivery to the bone is simply a reflection of the volume of blood flow [Ewing, 1928]. However, theories of preferential adhesion and the potential role of chemoattractants in colonization and subsequent growth are not discounted [Keller et al., 2001; Taichman et al., 2002; Cooper et al., 2003] as there is little doubt that the bone microenvironment provides a rich “soil” for the prostate cancer cell “seeds” [Paget, 1889]. For example, bone extracts induce at least a three-fold increase in invasion by PC-3 and DU145 cells compared with brain and other tissue extracts, demonstrating that bone contains significant migration and chemoinvasion promoting factors for prostate cancer cells [Jacob et al., 1999]. By purifying the bone extract, osteonectin was identified as the chemoattractant that promoted prostate cancer cell invasion [Jacob et al., 1999]. Blocking antibodies to the αvβ3 integrins have been shown to reduce prostate cancer cell adhesion to crude bone protein extract by 94% [Hullinger et al., 1998], suggesting the importance of the integrins in the process.

Numerous other factors contribute to prostate cancer cell proliferation in the bone, and many are mediated through the engagement of integrin receptors. Unlike prostate epithelial associated ECM, the main component of bone ECM is collagen type I which is a ligand for α2β1 and α3β1 integrins. Greater proliferation rates for prostate cancer cells are observed in cells grown on collagen I compared to plastic or fibronectin substrates; cell signaling through phosphatidylinositol 3-kinase (PI3K) and increased expression of cyclin D1 are implicated in this process [Kiefer and Farach-Carson, 2001]. Interestingly, osteopontin, a non-collagenous bone ECM component, stimulates proliferation of quiescent prostate epithelial cells more than collagen in an integrin-mediated manner [Elgavish et al., 1998], stimulates anchorage-independent growth of the human prostate cancer cell lines LNCaP and C4-2 [Thalmann et al., 1999], and induces PC-3 cell migration and invasion via αvβ3 integrin function [Angelucci et al., 2002].

Although more than 95% of the bone ECM is composed of collagen type I, other proteins are also deposited by osteoblasts during bone formation [Hauschka et al., 1986]. Co-culture of PC-3 cells with osteoblasts reveals that transforming growth factor-β1 (TGF-β) produced by osteoblasts stimulates PC-3 cell migration and invasion as well as increases α2β1 and α3β1 integrins expressions [Festuccia et al., 1999a]. Furthermore, osteoblast-conditioned medium stimulates the release of proteolytic enzymes urokinase plasminogen activator and matrix metalloproteinase-9 from prostate cancer cells [Festuccia et al., 1999b].

Although factors in the bone microenvironment promote prostate cancer cell growth,
prostate cancer cells also contribute to bone remodeling in a “vicious cycle” [Chung, 2003]. Because prostate cancer metastases are usually osteoblastic in nature, the role of bone morphogenetic proteins (BMPs) in the course of bone metastasis is quite intriguing since they contribute to bone formation. Bentley et al. [1992] first reported that the expression of BMP-6, a member of the TGF-β superfamily, was detected in prostate tissue samples of over 50% of patients with clinically defined metastatic prostate cancer, but not non-metastatic or benign prostate samples. Subsequent studies have confirmed the increased expression of BMP-6 in metastatic prostate cancer cells [Barnes et al., 1995; Hamdy et al., 1997; Autzen et al., 1998; Thomas and Hamdy, 2000]. It is believed that secretion of BMP-6, among other proteins, by prostate cancer cells contributes to osteoblastic lesions because BMP-6 stimulates osteoblastic differentiation of pluripotent mesenchymal [Ebisawa et al., 1999]. Furthermore, osteoblastic differentiation requires the activation of focal adhesion kinase (FAK), an immediate effector of the integrin signaling pathway [Tamura et al., 2001].

INTEGRIN REGULATION OF MOTILITY AND DYNAMIC CELL–SUBSTRATE INTERACTIONS

As discussed above, many steps of the metastatic cascade involve the establishment and termination of adhesive interactions between cancer cells and the ECM via integrins. However, integrins also regulate intracellular signaling pathways that control cytoskeletal organization, force generation, and survival [Hood and Cheresh, 2002]. This signal transduction is modulated in two directions: activation of integrins to bind to ligands produces “inside-out” signaling and generation of ligand bound integrins activates downstream intracellular kinases and GTPases causing “outside-in” signaling. In this “outside-in” signaling, ligand bound integrins cluster with structural and catalytic focal adhesion-associated proteins at cell–ECM junctions called focal adhesions. Because integrins do not possess kinase activity, the focal adhesion-associated protein FAK initiates the intracellular signaling cascade using its ability to recruit downstream effectors to the focal adhesion [Hood and Cheresh, 2002]. In prostate cancer, the highly tumorigenic PC-3 and DU145 cell lines have increased expression of FAK compared to the poorly tumorigenic LNCaP cells, suggesting a differential modulation of the integrin signaling pathway in metastatic prostate cancer cells [Slack et al., 2001].

Cell motility are a coordination of focal adhesion assembly at the leading edge of motile cells, providing traction for cell migration, and focal adhesion disassembly at the trailing edge of these cells, resulting in forward movement [Sastry and Burridge, 2000]. RhoGTPases, activated through integrin-mediated, focal adhesion-localized FAK and other tyrosine kinases, and G-protein receptors, appear to be key facilitators of these dynamics. These proteins and their associated downstream signals are elevated in malignant tissues but are almost non-existent in normal tissues and benign hyperplasias [Fritz et al., 2002; Kamai et al., 2002; Kostenuik et al., 1996].

Currently there are at least 18 known members of RhoGTPases. The best-characterized are Cdc42, Rac, and Rho [Sahai and Marshall, 2002]. Activated Cdc42 produces filipodia, actin-rich spikes that establish cell polarity by sensing tactic signals [Arthur and Burridge, 2001]. These extended antennae allow cells to detect changes in their surrounding and transduce intracellular signals to adjust to their microenvironment, a property which is crucial in cancer metastasis. Activated Rac coordinates focal adhesion assembly in lamellipodium and membrane ruffling [Ridley et al., 1992; Nobes and Hall, 1995; Clark et al., 1998]. These new focal adhesions establish a path for cancer cells to begin their quest to find more enriched “soil.” Activated Rho generates contractile forces that push a cell body toward the leading edge and can stimulate other downstream signaling pathways leading to stress fiber formation, cell contraction, or actin polymerization depending on cross-talk between Rac, Cdc42, and other Rho regulatory proteins [Ridley, 2001]. For example, inhibition of Rho kinase, a Rho downstream target, decreases prostate cancer cell chemotactic migration in vitro and tumor growth and angiogenesis in vivo [Somlyo et al., 2000, 2003]. As well, a putative Rho regulatory protein was recently identified that encodes a novel Src homology 3 domain-containing guanine nucleotide exchange factor (CSGEF) [Qi et al., 2003]. Expressed only in prostate and liver tissues, CSGEF mRNA levels are increased two-fold in the LNCaP prostate cancer...
cell line after androgen treatment, suggesting a possible role of CSGEF in modulating prostate cancer cell metastasis. G-protein receptor PAR1 activation of Rho similarly induces actin cytoskeletal reorganization (reviewed in [Whitehead et al., 2001]). In prostate cancer cells, this activation contributes to increased prostate cancer invasiveness [Chay et al., 2002; Cooper et al., 2003; Greenberg et al., 2003] and increased production of stress fibers in LNCaP cells treated with thrombin [Greenberg et al., 2003].

**PROSPECT: CAN INTEGRINS BE USED AS TARGETS TO PREVENT OR TREAT BONE METASTASES?**

Prostate cancer cells with varying degrees of malignancy exhibit differential expression of integrin receptors which leads to the ability of these cells to develop preferential binding or “sensing” of the microenvironment through different integrins [Edlund et al., 2001]. This raises questions to the importance of integrins in prostate cancer bone metastasis and to their feasibility as therapeutic targets. Unfortunately, the exact integrins involved in the various steps of prostate cancer metastasis remain undefined (See Table 1). Furthermore, the signaling pathways responsible for the regulation of the cell surface expression of integrins are unclear. For example, will inhibiting the “sensing” mechanism of the cancer cells through inhibition of the Cdc42 signaling pathway be sufficient to suppress metastasis? Or is there other mechanism(s) at work? The affinity and avidity of the integrin receptors can be modulated by many factors both from the outside and the inside of cells. Weakly attached cells cannot generate enough force for movement whereas highly adhesive forces can render cell immobility. We know that the ECM protein substrates regulate the affinity of the integrins, but what factors are regulating the avidity of the integrins? Zheng et al. [2000] have shown that LNCaP cells use the αvβ3 integrins to adhere to vitronectin and osteopontin. However, αvβ3 mediated cell migration and PI3K activation, through its downstream serine/threonine kinase Akt, upon interaction with vitronectin, whereas adhesion to osteopontin did not induce αvβ3-mediated cell migration and PI3K/AKT pathway activation, thus suggesting some unknown mechanism co-modulating the “outside-in” signaling pathway. Growth factors and signaling through the G-protein-coupled receptors have been known to activate RhoGTPases (reviewed in [Kjoller and Hall, 1999]). Which factor(s) in the microenvironments of the primary tumor, the circulation, and the target organ can activate integrin-mediated adhesion, dynamic cell structure, migration, and invasion? The answers to these questions will lead not only to a better understanding of the biology of prostate cancer metastasis but should also lead to the identification of therapeutic targets for the prevention and treatment of prostate cancer metastasis.

**ACKNOWLEDGMENTS**

The authors thank Chris Neeley and the Electron Microscopy Core Facility for their assistance with scanning electron microscopy.

**REFERENCES**


Prostate Cancer Bone Metastasis


